MCID: ADL008
MIFTS: 37

Adult Oligodendroglioma

Categories: Cancer diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Adult Oligodendroglioma

MalaCards integrated aliases for Adult Oligodendroglioma:

Name: Adult Oligodendroglioma 12 15
Adult Brain Oligodendroglioma 12 74
Grade Ii Adult Oligodendroglial Tumor 12
Oligodendroglioma, Adult 74

Classifications:



External Ids:

Disease Ontology 12 DOID:3186
MeSH 45 D009837
NCIt 51 C4014 C9376

Summaries for Adult Oligodendroglioma

MalaCards based summary : Adult Oligodendroglioma, also known as adult brain oligodendroglioma, is related to oligodendroglioma and pilomyxoid astrocytoma, and has symptoms including seizures and headache. An important gene associated with Adult Oligodendroglioma is IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2, Mitochondrial), and among its related pathways/superpathways are Citrate cycle (TCA cycle) and Peroxisome. The drugs Temozolomide and Lomustine have been mentioned in the context of this disorder. Affiliated tissues include brain, bone and bone marrow.

Related Diseases for Adult Oligodendroglioma

Diseases in the Oligodendroglioma family:

Adult Oligodendroglioma

Diseases related to Adult Oligodendroglioma via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 46)
# Related Disease Score Top Affiliating Genes
1 oligodendroglioma 29.9 IDH1 IDH2
2 pilomyxoid astrocytoma 10.0 FGFR1 NF1
3 pilocytic astrocytoma 9.9 IDH1 NF1
4 interval angle-closure glaucoma 9.9 IDH1 IDH2
5 enchondroma 9.9 IDH1 IDH2
6 intracranial chondrosarcoma 9.9 IDH1 IDH2
7 chondrosarcoma 9.9 IDH1 IDH2
8 cytogenetically normal acute myeloid leukemia 9.9 IDH1 IDH2
9 chondroblastic osteosarcoma 9.9 IDH1 IDH2
10 multiple enchondromatosis, maffucci type 9.9 IDH1 IDH2
11 intraductal papilloma 9.9 IDH1 IDH2
12 spindle cell hemangioma 9.9 IDH1 IDH2
13 periosteal chondrosarcoma 9.9 IDH1 IDH2
14 glioma susceptibility 1 9.9 IDH1 IDH2
15 adult astrocytic tumour 9.9 IDH1 IDH2
16 fibrillary astrocytoma 9.9 IDH1 IDH2
17 diffuse infiltrative lymphocytosis syndrome 9.9 IDH1 IDH2
18 drug-induced mental disorder 9.9 IDH1 IDH2
19 drug psychosis 9.9 IDH1 IDH2
20 astrocytoma 9.9 FGFR1 IDH1
21 undifferentiated pleomorphic sarcoma 9.9 IDH1 IDH2
22 2-hydroxyglutaric aciduria 9.9 IDH1 IDH2
23 bone marrow cancer 9.9 FGFR1 NF1
24 d-2-hydroxyglutaric aciduria 1 9.8 IDH1 IDH2
25 pineal parenchymal tumor of intermediate differentiation 9.8 IDH1 NF1
26 bile duct adenocarcinoma 9.8 IDH1 IDH2
27 enchondromatosis, multiple, ollier type 9.8 IDH1 IDH2
28 intrahepatic cholangiocarcinoma 9.8 IDH1 IDH2
29 cholangiocarcinoma 9.8 IDH1 IDH2
30 li-fraumeni syndrome 9.8 IDH1 NF1
31 giant cell glioblastoma 9.8 FGFR1 IDH1
32 gliosarcoma 9.7 FGFR1 IDH1
33 essential thrombocythemia 9.7 IDH1 IDH2
34 pilocytic astrocytoma of cerebellum 9.6 IDH1 IDH2 NF1
35 supratentorial cancer 9.6 IDH1 IDH2 NF1
36 cerebrum cancer 9.6 IDH1 IDH2 NF1
37 central nervous system cancer 9.6 IDH1 IDH2 NF1
38 myelofibrosis 9.6 IDH1 IDH2
39 bladder urothelial carcinoma 9.6 FGFR1 IDH1
40 nervous system cancer 9.6 IDH1 IDH2 NF1
41 brain cancer 9.6 IDH1 IDH2 NF1
42 brain stem glioma 9.6 FGFR1 IDH1 IDH2
43 myelodysplastic syndrome 9.5 IDH1 IDH2 NF1
44 myeloma, multiple 9.5 IDH1 IDH2
45 glioma 9.3 FGFR1 IDH1 IDH2 NF1
46 glioblastoma 9.3 FGFR1 IDH1 IDH2 NF1

Graphical network of the top 20 diseases related to Adult Oligodendroglioma:



Diseases related to Adult Oligodendroglioma

Symptoms & Phenotypes for Adult Oligodendroglioma

UMLS symptoms related to Adult Oligodendroglioma:


seizures, headache

Drugs & Therapeutics for Adult Oligodendroglioma

Drugs for Adult Oligodendroglioma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 164)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Temozolomide Approved, Investigational Phase 3,Phase 2,Phase 1 85622-93-1 5394
2
Lomustine Approved, Investigational Phase 2, Phase 3 13010-47-4 3950
3
Procarbazine Approved, Investigational Phase 2, Phase 3 671-16-9 4915
4
Vincristine Approved, Investigational Phase 2, Phase 3 2068-78-2, 57-22-7 5978
5
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
6
Donepezil Approved Phase 3,Phase 2 120014-06-4 3152
7 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
8 Alkylating Agents Phase 3,Phase 2,Phase 1
9 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1
10 Antimitotic Agents Phase 2, Phase 3,Phase 1
11 Antineoplastic Agents, Phytogenic Phase 2, Phase 3,Phase 1
12 Narcotics Phase 3
13 Adjuvants, Anesthesia Phase 3
14 Analgesics Phase 3,Phase 2
15 Anesthetics, Intravenous Phase 3
16 Liver Extracts Phase 3,Phase 2,Phase 1
17 Anesthetics, General Phase 3
18 Anesthetics Phase 3
19 Analgesics, Opioid Phase 3
20 Central Nervous System Depressants Phase 3,Phase 2
21 Peripheral Nervous System Agents Phase 3,Phase 2
22 Cola Phase 3,Phase 1
23 Cholinesterase Inhibitors Phase 3,Phase 2
24 Neurotransmitter Agents Phase 3,Phase 2,Early Phase 1,Not Applicable
25 Nootropic Agents Phase 3,Phase 2
26 Cholinergic Agents Phase 3,Phase 2
27
Bevacizumab Approved, Investigational Phase 2 216974-75-3
28
Dasatinib Approved, Investigational Phase 2 302962-49-8 3062316
29
Lenograstim Approved, Investigational Phase 2,Phase 1 135968-09-1
30
Busulfan Approved, Investigational Phase 2 55-98-1 2478
31
Thiotepa Approved, Investigational Phase 2 52-24-4 5453
32
Sirolimus Approved, Investigational Phase 2,Phase 1 53123-88-9 46835353 5284616 6436030
33
Miconazole Approved, Investigational, Vet_approved Phase 2,Phase 1 22916-47-8 4189
34
Everolimus Approved Phase 2,Phase 1 159351-69-6 70789204 6442177
35
Irinotecan Approved, Investigational Phase 2,Phase 1 100286-90-6, 97682-44-5 60838
36
Sunitinib Approved, Investigational Phase 2 557795-19-4, 341031-54-7 5329102
37
Carmustine Approved, Investigational Phase 2,Phase 1 154-93-8 2578
38
Etoposide Approved Phase 2,Phase 1 33419-42-0 36462
39
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
40
Cisplatin Approved Phase 2,Phase 1 15663-27-1 2767 441203 84093
41
Modafinil Approved, Investigational Phase 2 68693-11-8 4236
42
Pregabalin Approved, Illicit, Investigational Phase 2 148553-50-8 5486971
43
Levetiracetam Approved, Investigational Phase 2 102767-28-2 441341
44
Sodium Citrate Approved, Investigational Phase 2 68-04-2
45
Carboplatin Approved Phase 2,Phase 1 41575-94-4 10339178 38904 498142
46
Topotecan Approved, Investigational Phase 2 119413-54-6, 123948-87-8 60700
47
Tamoxifen Approved Phase 2 10540-29-1 2733526
48
Sargramostim Approved, Investigational Phase 2,Phase 1 123774-72-1, 83869-56-1
49
Aldesleukin Approved Phase 2 110942-02-4, 85898-30-2
50
Iodine Approved, Investigational Phase 1, Phase 2,Phase 2 7553-56-2 807

Interventional clinical trials:

(show top 50) (show all 82)
# Name Status NCT ID Phase Drugs
1 Radiation Therapy or Temozolomide in Treating Patients With Gliomas Completed NCT00182819 Phase 3 temozolomide
2 Observation or Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Low-Grade Glioma Completed NCT00003375 Phase 2, Phase 3 lomustine;procarbazine hydrochloride;vincristine sulfate
3 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
4 Donepezil in Treating Patients Who Have Undergone Radiation Therapy for Brain Tumors Completed NCT00369785 Phase 3 donepezil hydrochloride;Placebo
5 Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma Active, not recruiting NCT00978458 Phase 3 temozolomide
6 Proton Beam Radiation Therapy in Treating Patients With Low Grade Gliomas Unknown status NCT01024907 Phase 1, Phase 2
7 Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme Unknown status NCT00892177 Phase 2 dasatinib
8 Temozolomide in Treating Patients With Recurrent Oligodendroglial Tumors Completed NCT00003304 Phase 2 temozolomide
9 Combination Chemotherapy and Bone Marrow Transplantation or Peripheral Stem Cell Transplantation in Treating Patients With Oligodendroglioma Completed NCT00003101 Phase 2 busulfan;lomustine;procarbazine hydrochloride;thiotepa;vincristine sulfate
10 Temozolomide in Treating Patients With Recurrent Oligodendroglial Tumors Completed NCT00003731 Phase 2 temozolomide
11 Everolimus in Treating Patients With Recurrent Low-Grade Glioma Completed NCT00823459 Phase 2 Everolimus
12 Temozolomide in Treating Patients With Low-Grade Glioma Completed NCT00313729 Phase 2 temozolomide
13 Irinotecan in Treating Patients With Recurrent Glioma Completed NCT00003134 Phase 2 irinotecan hydrochloride
14 Irinotecan in Treating Patients With Progressive or Recurrent Malignant Glioma Completed NCT00003616 Phase 1, Phase 2 irinotecan hydrochloride
15 Sunitinib in Treating Patients With Recurrent Malignant Gliomas Completed NCT00499473 Phase 2 sunitinib malate
16 Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer Completed NCT00492089 Phase 2 bevacizumab;placebo
17 Carmustine in Treating Adults With Recurrent Supratentorial Low-Grade Glioma Completed NCT00003467 Phase 2 carmustine;polifeprosan 20 with carmustine implant
18 Chemotherapy Plus Peripheral Stem Cell Transplant in Treating Patients With Central Nervous System Cancer Completed NCT00007982 Phase 2 carmustine;cisplatin;cyclophosphamide;etoposide;thiotepa
19 Bevacizumab in Recurrent Grade II and III Glioma Completed NCT01164189 Phase 2 Temozolomide
20 Armodafinil in Treating Fatigue Caused By Radiation Therapy in Patients With Primary Brain Tumors Completed NCT01032200 Phase 2 Armodafinil
21 Levetiracetam or Pregabalin in Treating Seizures in Patients Undergoing Chemotherapy and/or Radiation Therapy For Primary Brain Tumors Completed NCT00629889 Phase 2 levetiracetam;pregabalin
22 Tamoxifen, Carboplatin, and Topotecan in Treating Patients With CNS Metastases or Recurrent Brain or Spinal Cord Tumors Completed NCT00541138 Phase 2 carboplatin;tamoxifen citrate;topotecan hydrochloride
23 Temozolomide in Treating Patients With Recurrent Glioblastoma Multiforme or Other Malignant Glioma Completed NCT00498927 Phase 2 temozolomide
24 Magnetic Resonance Imaging and Magnetic Resonance Spectroscopic Imaging in Evaluating Patients Who Are Undergoing Treatment for Gliomas Completed NCT00274755 Phase 2 chemotherapy
25 Carboplatin in Patients With Progressive Gliomas Completed NCT00002749 Phase 2 carboplatin
26 Thiotepa Followed by Peripheral Stem Cell or Bone Marrow Transplant in Treating Patients With Malignant Glioma Completed NCT00008008 Phase 2 cyclophosphamide;thiotepa
27 Pyrazoloacridine Plus Carboplatin in Treating Patients With Recurrent Glioma Completed NCT00005976 Phase 2 carboplatin;pyrazoloacridine
28 Biological Therapy Following Surgery and Radiation Therapy in Treating Patients With Primary or Recurrent Astrocytoma or Oligodendroglioma Completed NCT00004024 Phase 2
29 Phase II Studies Of Donepezil And Ginkgo Biloba In Irradiated Brain Tumor Completed NCT00070161 Phase 2 donepezil hydrochloride
30 Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Brain Cancers Completed NCT00002752 Phase 1, Phase 2
31 Temozolomide in Treating Patients With Progressive Low-Grade Glioma Completed NCT00003466 Phase 2 temozolomide
32 Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Brain Tumors Completed NCT00003461 Phase 1, Phase 2
33 Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors Completed NCT00002608 Phase 2 cisplatin;doxorubicin hydrochloride;tamoxifen citrate
34 Carboplatin, Melphalan, Etoposide Phosphate, Mannitol, and Sodium Thiosulfate in Treating Patients With Previously Treated Brain Tumors Recruiting NCT00303849 Phase 1, Phase 2 Carboplatin;Etoposide Phosphate;Mannitol;Melphalan;Sodium Thiosulfate
35 Temozolomide and Radiation Therapy in Treating Patients With Gliomas Active, not recruiting NCT00114140 Phase 2 Temozolomide
36 Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor Active, not recruiting NCT00049127 Phase 1, Phase 2 Imatinib Mesylate
37 Vaccine for Patients With Newly Diagnosed or Recurrent Low-Grade Glioma Active, not recruiting NCT01635283 Phase 2
38 Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer Active, not recruiting NCT00445965 Phase 2
39 Antineoplaston Therapy in Treating Patients With Recurrent or Refractory Oligodendroglioma Terminated NCT00003472 Phase 2 Antineoplaston therapy (Atengenal + Astugenal)
40 Temsirolimus and Perifosine in Treating Patients With Recurrent or Progressive Malignant Glioma Terminated NCT01051557 Phase 1, Phase 2 Perifosine;Temsirolimus
41 Functional Magnetic Resonance Imaging and 1H-Nuclear Magnetic Resonance Spectroscopic Imaging in Treating Patients With Newly Diagnosed Brain Tumors Withdrawn NCT00005083 Phase 2
42 Lonafarnib and Temozolomide in Treating Patients With Recurrent Primary Supratentorial Gliomas Unknown status NCT00083096 Phase 1 lonafarnib;temozolomide
43 Photodynamic Therapy With Porfimer Sodium in Treating Patients With Refractory Brain Tumors Unknown status NCT00002647 Phase 1 verteporfin
44 Stereotactic Radiosurgery in Treating Patients With Brain Tumors Completed NCT00019578 Phase 1
45 Alisertib and Fractionated Stereotactic Radiosurgery in Treating Patients With Recurrent High Grade Gliomas Completed NCT02186509 Phase 1 Alisertib
46 RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma Completed NCT01119599 Phase 1 Gamma-Secretase Inhibitor RO4929097;Temozolomide
47 Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction Completed NCT00030498 Phase 1 erlotinib hydrochloride
48 Tumor Tissue Analysis in Patients Receiving Imatinib Mesylate for Malignant Glioma Completed NCT00401024 Phase 1 imatinib mesylate
49 A Feasibility, Dose-Escalation Study Using Intracerebral Microdialysis to Assess the Neuropharmacodynamics of Temsirolimus in Patients With Primary or Metastatic Brain Tumors Completed NCT00784914 Phase 1 temsirolimus
50 Cellular Adoptive Immunotherapy Using Genetically Modified T-Lymphocytes in Treating Patients With Recurrent or Refractory High-Grade Malignant Glioma Completed NCT00730613 Phase 1

Search NIH Clinical Center for Adult Oligodendroglioma

Genetic Tests for Adult Oligodendroglioma

Anatomical Context for Adult Oligodendroglioma

MalaCards organs/tissues related to Adult Oligodendroglioma:

42
Brain, Bone, Bone Marrow, Liver, Kidney, Spinal Cord, Cerebellum

Publications for Adult Oligodendroglioma

Articles related to Adult Oligodendroglioma:

# Title Authors Year
1
Pre- and post-surgery MRSI predictive value in adult oligodendroglioma prognosis. ( 29902567 )
2018

Variations for Adult Oligodendroglioma

Expression for Adult Oligodendroglioma

Search GEO for disease gene expression data for Adult Oligodendroglioma.

Pathways for Adult Oligodendroglioma

Pathways related to Adult Oligodendroglioma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
11.27 IDH1 IDH2
2 11.07 IDH1 IDH2
3 10.77 FGFR1 IDH1
4
Show member pathways
9.74 IDH1 IDH2

GO Terms for Adult Oligodendroglioma

Cellular components related to Adult Oligodendroglioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 peroxisome GO:0005777 8.62 IDH1 IDH2

Biological processes related to Adult Oligodendroglioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 regulation of cell proliferation GO:0042127 9.37 FGFR1 NF1
2 tricarboxylic acid cycle GO:0006099 9.32 IDH1 IDH2
3 2-oxoglutarate metabolic process GO:0006103 9.26 IDH1 IDH2
4 NADP metabolic process GO:0006739 9.16 IDH1 IDH2
5 isocitrate metabolic process GO:0006102 8.96 IDH1 IDH2
6 glyoxylate cycle GO:0006097 8.62 IDH1 IDH2

Molecular functions related to Adult Oligodendroglioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein homodimerization activity GO:0042803 9.5 FGFR1 IDH1 IDH2
2 NAD binding GO:0051287 9.26 IDH1 IDH2
3 oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor GO:0016616 9.16 IDH1 IDH2
4 isocitrate dehydrogenase (NADP+) activity GO:0004450 8.96 IDH1 IDH2
5 isocitrate dehydrogenase activity GO:0004448 8.62 IDH1 IDH2

Sources for Adult Oligodendroglioma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....